Login

I cannot remember my username

Breakthrough Technology Alert

This is the best time to be investing in world-changing technologies, as unprecedented innovations are taking off right now...

In Breakthrough Technology Alert, Ray Blanco tirelessly researches these exciting new breakthrough technologies and tells you exactly what you need to do to profit from them.

Flash Sell! Grab a Double-Digit Gain on This Biotech

By Ray BlancoPosted August 13, 2018

We have new quarterly results from biotech companies, news of a clinical trial from an Alzheimer’s play, and analysis on the success of our latest pick. Ray has plenty of updates this week to keep your portfolio thriving…

You Must Be A Subscriber To View This Content.

If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!

Breakthrough Technology Alert

This is the best time to be investing in world-changing technologies, as unprecedented innovations are taking off right now… Breakthrough Technology Alert tirelessly researches these exciting new breakthrough technologies to keep you well informed, outline specific opportunities, and keep you ahead of the game.

LoginGet Access

Ray Blanco

Ray Blanco is the editor of Technology Profits Confidential as well as Breakthrough Technology Alert, Ray Blanco’s FDA Trader, Penny Pot Profits and Technology Profits Daily. Ray has been with Seven Figure Publishing for nine years. In 2018, his closed positions in Technology Profits Confidential averaged over 100% gains.

View More By Ray Blanco

Related Posts

NanoViricides Shows Oral Delivery and Anavex Benefits as Field of AD Drugs Narrows

By Patrick CoxPosted August 14, 2012

I have truly astounding news from NanoViricides (OTCBB: NNVC). First, however, allow me to respond to a friend who told me recently that I should have reminded my readers that I had predicted the failure of bapineuzumab, the Alzheimer's drug candidate jointly funded by Pfizer, Johnson & Johnson and Elan. So for the record, I told you so. In fact, the reason I got this right was that I listened to Dr. Cameron Durrant, formerly a top executive for several Big Pharma companies and Anavex Life Sciences Corp. (OTCBB: AVXL). Durrant knows the inside story when it comes to AD as well as the pharmaceutical industry.

Tapping Mobile Phone Profits

By Patrick CoxPosted May 27, 2008

I've just finished this month's newsletter. We are is preparing it now, so you'll have the electronic version soon. The "dead tree" version will follow shortly after.

The Rise of English as the World’s Lingua Franca

By Stephen PetranekPosted July 21, 2014

Greetings from Europe, where all appearances of trouble with the economies of the European Union have disappeared from view, blocked out by multiplying building cranes, full restaurants and packed stores. The recession that started in the United States seven years ago is now the longest and deepest in Europe in more than three decades. The U.S. began recovering five years ago, but Europe’s recovery is only about a year old. In the last two years, European stocks have risen about 30% yet still offer good value. And there are two interesting experiments being conducted by central banks at the moment. In America, the Fed is tightening by winding down the supply of money it has been pumping into the economy. In Europe, the central bank is doing the opposite -- aggressively stimulating the economy, including charging banks for holding onto too much cash.